These innovative molecules represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://dillanqsxe512973.vblogetin.com/45135405/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide